KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Assets (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Assets data on record, last reported at $513.6 million in Q4 2025.

  • For Q4 2025, Assets rose 213.21% year-over-year to $513.6 million; the TTM value through Dec 2025 reached $513.6 million, up 213.21%, while the annual FY2025 figure was $513.6 million, 213.21% up from the prior year.
  • Assets reached $513.6 million in Q4 2025 per RIGL's latest filing, up from $242.5 million in the prior quarter.
  • Across five years, Assets topped out at $513.6 million in Q4 2025 and bottomed at $115.3 million in Q3 2023.
  • Average Assets over 5 years is $173.4 million, with a median of $144.2 million recorded in 2022.
  • Peak YoY movement for Assets: tumbled 38.02% in 2022, then soared 213.21% in 2025.
  • A 5-year view of Assets shows it stood at $167.3 million in 2021, then fell by 19.75% to $134.3 million in 2022, then decreased by 12.7% to $117.2 million in 2023, then soared by 39.88% to $164.0 million in 2024, then skyrocketed by 213.21% to $513.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $513.6 million in Q4 2025, $242.5 million in Q3 2025, and $206.7 million in Q2 2025.